Related references
Note: Only part of the references are listed.FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
Suparna Wedam et al.
CLINICAL CANCER RESEARCH (2020)
Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET).
Cynthia Huang Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Mrinal M. Gounder et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Alison M. Pease et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Alison M. Pease et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2016)
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2016)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Martin Fassnacht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Interindividual variation in nucleotide excision repair genes and risk of endometrial cancer.
JM Weiss et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)